移植受者合并移植物抗宿主病后白癜风风险研究
结果显示移植受者白癜风风险显著升高(AHR 1.73,95%CI 1.35-2.22),造血干细胞移植受者最高(AHR 12.69,95%CI 5.11-31.50),合并GVHD者达AHR 24.09(95%CI 9.16-63.35)。
要点
- 移植受者白癜风风险高于一般人群,需提高警惕
- 造血干细胞移植及合并GVHD者白癜风风险最高
- 建议对移植受者采取多学科协作监测
核心结论
- 移植受者白癜风风险显著升高,尤其是造血干细胞移植受者、异基因移植者及合并GVHD者。
主要发现
- 移植受者白癜风风险高于对照(AHR 1.73;95%CI 1.35-2.22)。
- 造血干细胞移植受者风险最高(AHR 12.69;95%CI 5.11-31.50)。
- 异基因移植者AHR 14.43(95%CI 5.61-37.15),自体移植者AHR 5.71(95%CI 1.20-3.18)。
- 合并GVHD者AHR 24.09(95%CI 9.16-63.35),无GVHD者AHR 8.21(95%CI 3.08-21.87)。
临床怎么用
- 临床医生应认识移植及GVHD患者的白癜风风险,采用多学科方法进行监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Vitiligo is a multifactorial, depigmenting skin disorder characterized by selective loss of melanocytes. Large-scale studies are lacking to determine the risk of vitiligo in transplant recipients with graft-vs-host disease (GVHD). OBJECTIVE: To investigate the incidence rates and risk of vitiligo in patients who had received solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT) overall and by HSCT graft type and concomitant GVHD. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study included data from the National Health Insurance Service database of Korea for patients aged 20 years or older who had received a transplant (SOT or HSCT) between January 2010 and December 2017, with follow-up until December 2019. A cohort of age- and sex-matched (1:5) control individuals who did not receive a transplant was included for comparison. Data were analyzed from July 2021 to December 2021. EXPOSURE: Transplant (SOT or HSCT) and GVHD. MAIN OUTCOMES AND MEASURES: The main outcome was risk of vitiligo, assessed using multivariable Cox proportional hazards regression analyses adjusting for potential confounding factors. RESULTS: The study included 23 829 patients who had undergone SOT or HSCT (62.78% male; mean [SD] age, 49.58 [11.59] years) and 119 145 age- and sex-matched controls. Patients who had undergone transplant had a significantly higher risk of vitiligo compared with controls (adjusted hazard ratio [AHR], 1.73; 95% CI, 1.35-2.22). Risk of vitiligo was also slightly higher in kidney transplant recipients and liver transplant recipients compared with the controls but was highest in HSCT recipients (AHR, 12.69; 95% CI, 5.11-31.50). Patients who had received allogeneic grafts (AHR, 14.43; 95% CI, 5.61-37.15), those who had received autologous grafts (AHR, 5.71; 95% CI, 1.20-3.18), those with comorbid GVHD (AHR, 24.09; 95% CI, 9.16-63.35), and those without GVHD (AHR, 8.21; 95% CI, 3.08-21.87) had a higher risk of vitiligo compared with controls. CONCLUSION AND RELEVANCE: In this study, risk of vitiligo was significantly higher in transplant recipients, especially in HSCT recipients and those with allogeneic grafts or comorbid GVHD. These findings provide new insights into the association between the risk of vitiligo and transplant and GVHD. Clinicians should be aware of these risks, implementing a multidisciplinary approach for monitoring.
引用
- Bang CH, Park HE, Kim YH, et al. Risk of Subsequent Vitiligo in Transplant Recipients With Comorbid Graft-vs-Host Disease. JAMA Dermatol. 2024. PMID: 38091023. doi:10.1001/jamadermatol.2023.4933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。